Results of the main studies of interferon-α (IFN-α) alone or in combination with low dose cytosine arabinoside (LDAC).The studies are ordered by year of publication. Notice that the dose of IFN-α is the dose that was scheduled. The dose that was actually given ranged from less than 50% to 80% of scheduled. In the study of Schofield et al30 IFN-α was scheduled daily for the first month and three times a week thereafter. In the Benelux study38 IFN-α was scheduled five times a week.
| . | . | IFN-α dose (MIU/day) . | No. of cases . | Major cytogenetic response* . | 5-year survival . |
|---|---|---|---|---|---|
| * Major cytogenetic response = Ph neg metaphases 66-100%. | |||||
| 1 Multicenter non-randomized study | |||||
| 2 Single center randomized study of IFN-α versus conventional chemotherapy. | |||||
| 3 Multicenter non-randomized study | |||||
| 4 Multicenter randomized study of IFN-α versus IFN-α + LDAC. | |||||
| Abbreviations: ICSG, Italian Cooperative Study Group | |||||
| Ozer et al 1993 | IFN-α 1 | 5/m2 | 128 | 24% | 52% |
| ICSG on CML 1994 | IFN-α 2 | 5/m2 | 218 | 19% | 60% |
| Schofield et al 1994 | IFN-α 3 | 2/m2 | 41 | 17% | 62% |
| Hehlmann et al 1994 | IFN-α 2 | 5/m2 | 133 | 6% | 58% |
| Kantarjian et al 1995 | IFN-α 3 | 5/m2 | 274 | 38% | 62% |
| Allan et al 1995 | IFN-α 2 | 5/m2 | 293 | 10% | 50% |
| Ohnishi et al 1995 | IFN-α 2 | 5/m2 | 85 | 15% | 63% |
| Thaler et al 1996 | IFN-α 1 | 3.5 total | 80 | 12% | 50% |
| Guilhot et al 1997 | IFN-α 4 | 5/m2 | 361 | 21% | 62% |
| Guilhot et al 1997 | IFN-α+LDAC4 | 5/m2 | 360 | 35% | 70% |
| Benelux 1998 | IFN-α 2 | 3 total | 100 | 16% | 54% |
| Mahon et al 1998 | IFN-α 3 | 5/m2 | 116 | 43% | 68% |
| Kantarjian et al 1999 | IFN-α+LDAC3 | 5/m2 | 186 | 45% | 68% |
| ICSG on CML 1999 | IFN-α1 | 5/m2 | 272 | 22% | 63% |
| Lindauer et al 1999 | IFN-α+LDAC1 | 5 total | 65 | 11% | 56% |
| Kloke et al 2000 | IFN-α3 | 4/m2 | 71 | 30% | 60% |
| ICSG on CML 2001 | IFN-α4 | 5/m2 | 263 | 18% | 65% |
| ICSG on CML 2001 | IFN-α+LDAC4 | 5/m2 | 275 | 28% | 68% |
| . | . | IFN-α dose (MIU/day) . | No. of cases . | Major cytogenetic response* . | 5-year survival . |
|---|---|---|---|---|---|
| * Major cytogenetic response = Ph neg metaphases 66-100%. | |||||
| 1 Multicenter non-randomized study | |||||
| 2 Single center randomized study of IFN-α versus conventional chemotherapy. | |||||
| 3 Multicenter non-randomized study | |||||
| 4 Multicenter randomized study of IFN-α versus IFN-α + LDAC. | |||||
| Abbreviations: ICSG, Italian Cooperative Study Group | |||||
| Ozer et al 1993 | IFN-α 1 | 5/m2 | 128 | 24% | 52% |
| ICSG on CML 1994 | IFN-α 2 | 5/m2 | 218 | 19% | 60% |
| Schofield et al 1994 | IFN-α 3 | 2/m2 | 41 | 17% | 62% |
| Hehlmann et al 1994 | IFN-α 2 | 5/m2 | 133 | 6% | 58% |
| Kantarjian et al 1995 | IFN-α 3 | 5/m2 | 274 | 38% | 62% |
| Allan et al 1995 | IFN-α 2 | 5/m2 | 293 | 10% | 50% |
| Ohnishi et al 1995 | IFN-α 2 | 5/m2 | 85 | 15% | 63% |
| Thaler et al 1996 | IFN-α 1 | 3.5 total | 80 | 12% | 50% |
| Guilhot et al 1997 | IFN-α 4 | 5/m2 | 361 | 21% | 62% |
| Guilhot et al 1997 | IFN-α+LDAC4 | 5/m2 | 360 | 35% | 70% |
| Benelux 1998 | IFN-α 2 | 3 total | 100 | 16% | 54% |
| Mahon et al 1998 | IFN-α 3 | 5/m2 | 116 | 43% | 68% |
| Kantarjian et al 1999 | IFN-α+LDAC3 | 5/m2 | 186 | 45% | 68% |
| ICSG on CML 1999 | IFN-α1 | 5/m2 | 272 | 22% | 63% |
| Lindauer et al 1999 | IFN-α+LDAC1 | 5 total | 65 | 11% | 56% |
| Kloke et al 2000 | IFN-α3 | 4/m2 | 71 | 30% | 60% |
| ICSG on CML 2001 | IFN-α4 | 5/m2 | 263 | 18% | 65% |
| ICSG on CML 2001 | IFN-α+LDAC4 | 5/m2 | 275 | 28% | 68% |